AbbVie Inc. (ABBV) Stock Analysis - DCF Valuation & AI Disruption Risk

AbbVie is the clearest patent-cliff-management success story in the group and has essentially nothing to do with AI: Humira sales collapsed from a $21.2B 2022 peak toward single-digit billions after 2023 biosimilar entry, but AbbVie replaced that revenue almost entirely with Skyrizi ($4.48B in Q1 2026) and Rinvoq ($2.12B in Q1 2026), which the company projects will together exceed $30B by 2027 -- above Humira's peak. Morningstar's most recent (July 2026) coverage explicitly credits this transition with supporting 'lengthy patent protection and a wide moat,' and AbbVie has layered on the Apogee acquisition to extend its immunology pipeline further. The durable risk is not AI disruption but the next wave of immunology competition and eventual loss of exclusivity on Skyrizi/Rinvoq themselves later this decade, plus continued residual Humira erosion dragging on reported growth. Watch combined Skyrizi/Rinvoq growth against AbbVie's own $30B 2027 target.

A.L. Capital Advisory's model produces a blended fair-value range (25% pure DCF, 75% analyst consensus for well-covered names) of $233 (bear case) to $412 (bull case) for AbbVie Inc. (ABBV). At $246.04, the margin of safety vs. blended base case is +24% (positive = discount to fair value; negative = premium). The bear-to-bull spread reflects genuine sensitivity to the two dominant DCF inputs: the terminal growth rate and the CAPM cost of equity (this model discounts EPS, an equity-level metric, so the cost of equity rather than a debt-weighted WACC is the applicable discount rate). Terminal value typically accounts for 60-80% of total intrinsic value in most equity DCF models, which is why a range is more analytically sound than a point estimate. The central analytical question is not what the DCF outputs as a single number but which growth trajectory the current market price already discounts. All DCF analysis follows CFA Institute standards and is conducted by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →

AbbVie Inc. (ABBV) carries a Strong Buy quantitative rating from A.L. Capital Advisory, set by Discounted Cash Flow margin-of-safety band with no analyst-conviction overlay applied. Five-factor model scoring (Value, Quality, Momentum, Volatility, Size) and CVaR tail risk measurement are shown separately on the page. At $246.04, the margin of safety vs. blended base fair value is +24% (blended fair-value range: $233 bear – $412 bull). That places the current price in the Fair Range zone of A.L. Capital Advisory's DCF framework, which sets the quantitative grade component that determines this rating. Composite factor score: 3.5/5. Strongest factor: Volatility (5.0/5). Weakest factor: Value (2.0/5). Trailing P/E: 68.9x. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Rating Methodology (this page) →

Wall Street consensus target for ABBV: $273.39 (+11.1% upside from the current price of $246.04). The analyst target range spans $200.00 (most bearish) to $328.00 (most bullish). Consensus recommendation: Buy. Note that analyst price targets typically reflect a 12-month forward horizon and are derived from a blend of DCF, comparable-company, and sum-of-the-parts analysis. A.L. Capital Advisory's Strong Buy composite rating is calculated from the blended margin-of-safety grade, applicable automatic fundamental penalties, and a disclosed qualitative analyst-conviction overlay — not from five-factor scores or CVaR, which are supporting diagnostics shown elsewhere on this page. The displayed blended fair value combines the standalone DCF output with Street consensus for well-covered names (see the DCF Assumptions box for the exact blend weight), so it does not track Street consensus mechanically, but it is not fully independent of it either. When the composite rating and the Street consensus recommendation diverge, the divergence itself is informative: it can reflect differences in time horizon, valuation methodology, or the degree to which the current price already discounts the consensus case. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Data & Sources (this page) →

ABBV five-factor scores (A.L. Capital Advisory, 1–5 scale): Value 2.0/5 (below average) — measures the trailing P/E multiple versus the sector median (not the DCF or blended fair-value range, which are separate metrics on this page); Quality 3.0/5 (neutral) — captures profitability metrics including return on equity and net margin (9.8%) — sustained above-peer ROE and margins are the model's proxy for economic moat and pricing power; Momentum 3.0/5 (neutral) — reflects recent price trajectory and earnings surprise consistency; Volatility 5.0/5 (strong) — inverse measure derived from beta, where lower historical volatility earns a higher score; Size 4.5/5 (strong) — market capitalisation rank (mega-cap $1T+ scores 5/5). Composite: 3.5/5. Factor scores above 4.0 signal a tailwind in that dimension; below 2.0 signals a material headwind. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory.

The 95th-percentile Conditional Value at Risk (CVaR) for ABBV on a one-month horizon is -10.3%. CVaR represents the expected average loss in the worst 5% of monthly outcomes — a more conservative tail risk measure than standard VaR, which only marks the loss threshold. Beta of 0.28 indicates below-market systematic sensitivity — beta measures historical sensitivity to market moves, not total volatility. For reference, a diversified S&P 500 ETF carries a one-month CVaR of roughly -8% to -12% in normal market conditions; individual equity CVaR is higher due to idiosyncratic risk. At the portfolio level, what matters is the marginal CVaR contribution of each holding — not its standalone figure. The A.L. Capital Advisory Portfolio Health Check quantifies each position's marginal tail-risk contribution across your entire holdings. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: CVaR & Tail-Risk Methodology →

Higher-conviction trigger: Evidence supporting the upper end of the Strong Buy range, such as accelerating earnings surprise magnitude combined with improvement in the Value factor score — specifically if the current 68.9x P/E is supported by an upward revision to DCF terminal growth assumptions. Downgrade trigger: An earnings miss at current valuations (68.9x trailing P/E) where there is limited earnings cushion to absorb negative surprises; or a sustained reversal in the Quality and Momentum factor scores for two or more consecutive quarters. These triggers are reassessed each time the underlying fundamentals, price, or earnings data refresh — the current Strong Buy rating is not held on a fixed review calendar. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Rating Methodology (this page) →

ABBV has beaten consensus EPS estimates in 3 of the 4 most recently reported quarters (75%) — indicating consistent delivery across the latest 4 reported quarters. The most recent reported quarter beat consensus by 1.1%. Sustained above-consensus delivery supports both the Momentum and Quality factor scores and provides a tailwind to the current rating. Across the 4 most recently reported quarters with valid consensus data, a beat rate above 70% signals consistent execution in this model, while a rate below 50% typically corresponds to a Momentum factor score of 3.0/5 or below. Earnings surprise magnitude and direction are incorporated into the Momentum and Quality dimensions of the five-factor scoring model. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Earnings History (this page) →

ABBV carries a beta of 0.28 (low-volatility / defensive relative to the broad equity market). A beta above 1.0 means the position amplifies market moves in both directions at a typical portfolio weight. Strongest peer co-movement: JNJ (0.47), PFE (0.39), LLY (0.37). Holding ABBV alongside these names in the same portfolio increases concentration risk. True portfolio risk is a function of the full covariance structure — a single stock's beta does not reveal its marginal contribution to portfolio tail loss. The A.L. Capital Advisory Portfolio Health Check quantifies concentration risk (Herfindahl-Hirschman Index), pairwise correlations, and marginal CVaR contribution across all your holdings. If a single position such as this one makes up an outsized share of your net worth — employer stock, RSUs, or concentrated equity compensation — a Strategic Session builds the sequencing plan and the written allocation that follows from it. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Ledoit-Wolf Covariance Framework →

A.L. Capital Advisory analyses AbbVie Inc. (ABBV) using a four-part quantitative research framework grounded in CFA Institute standards (not all four parts feed the composite rating formula directly — see below). (1) DCF Valuation: a two-stage earnings-based DCF that projects EPS (not free cash flow) under bear and bull assumptions, discounts at the CAPM cost of equity (the applicable rate for an equity-level metric like EPS, not a debt-weighted WACC) to produce an intrinsic value range with margin-of-safety calculation. (2) Five-Factor Scoring: each equity is scored 1–5 on Value, Quality, Momentum, Volatility, and Size. (3) CVaR Tail Risk: 95th-percentile Conditional Value at Risk from historical simulation of daily returns on a one-month horizon. (4) Earnings Surprise Analysis: quarterly beat rate and magnitude, shown for context alongside the factor scores. The current Strong Buy composite rating for ABBV is calculated separately from this broader framework: it consists of a Strong Buy quantitative grade, any automatic fundamental penalty, and a disclosed qualitative analyst-conviction overlay — see this page's Rating Methodology section for the exact formula. Five-factor scoring, CVaR and earnings surprise analysis below are supporting research diagnostics shown separately on this page; they are not direct numerical inputs into this specific composite-rating calculation. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →  ·  CVaR & Tail-Risk Methodology →